2019 China Health Industry Summit successfully held in Guangzhou

On November 19, China business report leader 21st century economic report successfully held "China Health Industry Summit 2019" in Guangzhou This summit focuses on the social responsibility of the great health industry, the response of pharmaceutical enterprises under the "policy city", the discussion of new opportunities for pharmaceutical investment and pharmaceutical biology, and invites guests from government agencies, global industry leaders, technology pioneers and top investment institutions to gather, aiming to build a new multi energy efficiency communication platform of "production, learning, research and broadcasting" and jointly promote the great health industry Development Zhang Zhibing, general manager of Nanfang finance and economics all media group, said in his speech that the medical and health industry has its own unique advantages It is an industry less affected by the economic cycle, because the people's demand for medical and health is constantly increasing regardless of the external environment "But also because of this, the public has put forward higher requirements for the quality of medical and health products and the reputation of enterprises The enterprises in it are also thinking about ensuring the quality of products and performing their social responsibilities better These elements will gradually become an important part of the enterprise brand and a significant symbol of the core competitiveness." Zhang Zhibing said On the same day, the summit also released the report on social responsibility of China's listed health care companies in 2019 As the second social responsibility report released to the public for the 21st century economic report, the report initiated the quantitative evaluation system of the social responsibility of medical and health enterprises based on multiple evaluation systems such as the sustainable development report guide organized by the global report initiative, and continued to improve and refine the seven audit dimensions of economic performance and market performance, employee rights and interests, environmental protection, etc on the A-share More than 300 medical listed companies in the city were graded, compared, screened and sorted out, and the top five enterprises were analyzed in depth This year's policies in the big health sector are still intensive and heavy The new round of belt purchase, the adjustment and negotiation of the medical insurance catalogue, the tax reduction of rare diseases, the encouragement of generic drugs, the construction of unified medical insurance information system, the overhaul of the drug administration law, the health China action - cancer prevention and control implementation plan (2019-2022), etc are all reshaping the industry pattern from different perspectives, putting forward a higher and newer test for the social responsibility of enterprises In September this year, the purchase result of the second tire quantity was announced For the price to be awarded this time, the price of many products was called "floor price" and "cabbage price" In the new round of market competition, the price fight changed the competition mode among enterprises The volume procurement also makes the original research drugs of "expired" multinational pharmaceutical companies face a real "patent cliff", but the local pharmaceutical companies mainly focusing on generic drugs are also very difficult, During this period, the winning pharmaceutical companies are facing a sharp decline in profits, and need to expand more powerful product lines and high-profit products to ensure supply; while the market space of the unsuccessful pharmaceutical companies is compressed, how to transform is what these pharmaceutical companies are facing In this historical stage of transition, the regulatory restriction on the social responsibility of pharmaceutical enterprises did not reduce the requirements On the contrary, the new regulations of the industry were pushed by higher standards Under the new situation, how to abide by business ethics, ensure production safety, product quality, protect the legitimate rights and interests of employees, occupational health, and achieve cost control without environmental pollution under the compression of profit space are the challenges facing enterprises On August 20 this year, a long-awaited national health insurance catalog was published The National Medical Security Bureau and the Ministry of human resources and social security issued the notice on printing and distributing (medical insurance Fa [2019] No 46), and officially published the list of drugs for the regular access part of the national basic medical insurance, work injury insurance and maternity insurance On November 11, the National Health Insurance Bureau officially started this round of negotiations How to improve the drug accessibility of patients? Reasonable price reduction into medical insurance can benefit more patients, which is also an important indicator of corporate social responsibility According to iqvia data, in 2018, the growth contribution rate of blood and hematopoietic organs, anti-tumor and immunomodulator in Chinese hospital drug market was the highest, 13.1% and 12% respectively In terms of market performance, the volume of drugs entering the national medical insurance is obvious Due to the continuous impact of the implementation of medical insurance negotiation and accelerated implementation of drug centralized bidding and purchase, the overall market improved significantly in the second quarter of 2019 This year, some drugs are facing the fate of being kicked out Some drugs are ready to be listed About 70 of them may need to participate in negotiations In the absence of a particularly high growth rate of the medical insurance fund, each of them is facing a grim situation At the same time, how to balance the relationship between budget and value, and how to ensure fairness and accessibility have become the issues to test all parties In recent years, China's big health industry has grown rapidly into a national strategic industry However, with the fermentation of vaccine events, APIs and other issues, social responsibility and product quality and safety have become the key words of the medical and health industry The lack of social responsibility and ethical crisis of some enterprises have made the sustainable development of the whole industry stand at a new turning point The continuous promotion of "healthy China" strategy brings development opportunities to the big healthy market, and the implementation of social responsibility is the basis for the development of the industry Based on the responsibility of the media, 21st century economic report has repeatedly stressed that fulfilling social responsibility is the behavior attitude that health industry must adhere to In this context, the 21st century economic report has been engaged in the collection and compilation team of medical and health reports for a long time About 300 A-share and Hong Kong share medical and health listed companies have been selected again to quantify the social responsibility of each enterprise from the aspects of economic benefits, environmental protection, product quality and safety, fair competition, employee compensation, social welfare, social responsibility reports, etc From the data point of view, in terms of social responsibility report, there are 117 enterprises with less than 10 scores in biopharmaceutical sector, accounting for 60% of the statistical data; 36 enterprises with less than 10 scores in medical device consumables sector, accounting for 65% of the statistical data; 21 enterprises with less than 10 scores in medical service sector, accounting for 55% of the total statistical data In terms of social responsibility, Sinopharm consistently obtained a full score of 20 points There are 59 enterprises in the biopharmaceutical sector, accounting for 37% of the statistical data There are 23 enterprises in the medical device consumables sector, accounting for 42% of the statistical data In terms of social welfare, there are 11 Enterprises, accounting for 29% of the statistical data In terms of environmental protection, golden domain medicine has a full score of 20 points, and 63 enterprises in the biopharmaceutical sector have obtained less than 10 points, accounting for 40% of the statistical data; 34 enterprises in the medical device consumables sector have obtained less than 10 points, accounting for 62% of the statistical data; 25 enterprises in the medical service sector have obtained less than 10 points, accounting for 66% of the statistical data Among 195 Biopharmaceutical Enterprises, more than 110 enterprises have received administrative punishment or serious violation, accounting for 56% of the statistical data; among medical device consumables enterprises, 28 enterprises have received administrative punishment or serious violation, accounting for 51% of the statistical data There are 20 medical service enterprises that have received administrative punishment or serious violations, accounting for 53% of the statistical data From the above data, China's biopharmaceuticals, medical equipment consumables, medical services and other enterprises still face space for further improvement in social responsibility, social welfare, environmental protection and other aspects In fact, at present, the social responsibility meeting of pharmaceutical enterprises has gradually become an important part of the corporate brand and a significant symbol of the core competitiveness As an enterprise in the new historical opportunities and challenges of soft power, it has become increasingly important In the world, more attention is paid to corporate social responsibility At present, with the improvement of their strength, Chinese pharmaceutical enterprises are gradually internationalizing, moving forward from a big pharmaceutical country to a powerful pharmaceutical country, and the social responsibility system is also being implemented in a new or even higher than international standards, which is a steady development path At the end of the 2019 China Health Industry Summit, the annual China Health Industry sunshine award was officially announced The "sunshine" award of China's big health industry was sponsored by 21st century economic report in 2017 According to 21st century economic report, fulfilling social responsibility is the behavior attitude that health industry must adhere to and the bottom line that big health enterprises must adhere to For this reason, in addition to focusing on financial indicators, industry scale and other indicators, social responsibility is listed as the most important evaluation indicator According to reports, more than 300 listed health and medical companies were selected in this selection, including seven indicators, namely, economic efficiency, environmental protection, product quality and safety, fair competition, employee compensation, social welfare and whether to issue social responsibility reports, and the strength of enterprises to help poverty was comprehensively investigated According to the open and transparent objective data, combined with the scoring results of the seven indicators of social responsibility, the best enterprises and products are finally selected These enterprises, people and products are the benchmark to advocate and promote "social responsibility" as the moral bottom line that must be adhered to in the development of health industry Wuxi yaomingkant new drug development Co., Ltd China Resources Sanjiu Pharmaceutical Co., Ltd Shanghai Fosun Pharmaceutical (Group) Co., Ltd China Resources Jiangzhong Pharmaceutical Group Co., Ltd Sichuan Kelun Pharmaceutical Co., Ltd Chengdu Kanghong Pharmaceutical Group Co., Ltd Novartis group (China) Shanxi guangyuyuan Guoyao Co., Ltd Meinian Health Industry Holding Co., Ltd Yunnan Watson Biotechnology Co., Ltd Taikangzhijia (Beijing) Investment Co., Ltd Micro medical group (Zhejiang) Co., Ltd Zhejiang haixinhui Technology Co., Ltd Shenzhen Qianhai life happiness home nursing home Shandong step Pharmaceutical Co., Ltd -- the charity project of "Tongxin · co Founding China" Gene seq-200 / 2000 gene sequencer